You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Nimbus, Shire to co-develop rare disease therapies

Nimbus Discovery LLC, a Cambridge biotechnology company, said Wednesday it has forged a co-development agreement with Shire plc that will focus on small molecule treatments for several rare genetic diseases.

Financial terms of the agreement are not being disclosed.

Continue reading below

Shire operates from a $500 million campus in Lexington. About a year ago, it reported having nearly nearly 1,650 full-time employees in Massachusetts.

Shire’s new chief executive recently cited the development of treatments for rare diseases as a company priority.

The agreement between Shire and Nimbus looks to focus on small molecule treatments for several rare genetic diseases known as lysosomal storage disorders, or LSDs. LSDs are inherited metabolic disorders caused by a lack of enzymes that normally eliminate unwanted substances in human cells. Lysosomal storage diseases predominantly affect children, many of which die within a few months or years of birth if untreated.

Under the agreement, the plan is to use Nimbus’s computational chemistry approach to discover and develop disease-altering therapies, Nimbus said in its press release.

This is the first deal announced through Shire’s strategic alliance with Atlas Venture, which identifies investments for early stage venture creation around rare genetic diseases.

Chris Reidy can be reached at
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of